Podcast appearances and mentions of Michael Wang

Send us a text"RAISE CAPITAL LIKE A LEGEND: https://offer.fundraisecapital.co/free-ebook/"Hey, welcome to another episode of Making Billions, I'm your host, Ryan Miller, and today I have my dear friend Michael Wang. Michael is the founder and CEO of Prometheus, an invite only platform connecting billion dollar family offices with each other and tailor investment opportunities. He served as the managing partner at Cypress Funds, one of the oldest hedge funds still in existence.  Michael has been featured and quoted in Bloomberg, Forbes, Fortune, Business Insider, Entrepreneur, Market Watch and Institutional Investor. So what does this mean? Well, it means that Michael understands how to raise capital the right way, and he's about to teach you and I the fundamental differences between raising capital as an amateur versus raising capital like the pros.Subscribe on YouTube:https://www.youtube.com/channel/UCTOe79EXLDsROQ0z3YLnu1QQConnect with Ryan Miller:Linkedin: https://www.linkedin.com/in/rcmiller1/Instagram: https://www.instagram.com/makingbillionspodcast/Twitter: Health Supplement Business MasteryGrow your dietary supplement D2C eCommerce business. Listen on: Apple Podcasts SpotifySupport the showDISCLAIMER: The information in every podcast episode “episode” is provided for general informational purposes only and may not reflect the current law in your jurisdiction. By listening or viewing our episodes, you understand that no information contained in the episodes should be construed as legal or financial advice from the individual author, hosts, or guests, nor is it intended to be a substitute for legal, financial, or tax counsel on any subject matter. No listener of the episodes should act or refrain from acting on the basis of any information included in, or accessible through, the episodes without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from a lawyer, finance, tax, or other licensed person in the recipient's state, country, or other appropriate licensing jurisdiction. No part of the show, its guests, host, content, or otherwise should be considered a solicitation for investment in any way. All views expressed in any way by guests are their own opinions and do not necessarily reflect the opinions of the show or its host(s). The host and/or its guests may own some of the assets discussed in this or other episodes, including compensation for advertisements, sponsorships, and/or endorsements. This show is for entertainment purposes only and should not be used as financial, tax, legal, or any advice whatsoever.

The global tech industry depends on Taiwan's semiconductor chips and many believe the sector plays a key role in the island's national security, helping stave off an invasion from mainland China. But as relations between China and Taiwan worsen, some countries are taking steps to become less reliant on Taiwanese chips. Already, the US, Germany and Japan have lured Taiwanese semiconductor makers to their own shores. Could that make Taiwan a more vulnerable target for attack?Presenter James Kynge visits the island and speaks to FT greater China correspondent Kathrin Hille, Taiwan's science and technology minister Cheng-Wen Wu, the president of Taiwan's semiconductor industry association Chih-I Wu, UMC associate vice-president Michael Wang, and Hsin-mei Cheng, writer and producer of 'Zero Day', a TV show about a hypothetical invasion from the mainland.Free links to read more on this topic:US and Taiwan seek to strengthen drone supply chain to keep out China Taiwan's new leader faces China threat and voters left behind by chip boom Taiwan on the faultline Presented by James Kynge. Edwin Lane is the senior producer. The producer is Josh Gabert-Doyon. Executive producer is Manuela Saragosa. Sound design by Sam Giovinco, with original music from Metaphor Music. The FT's head of audio is Cheryl Brumley. Special thanks to Kathrin Hille.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

In the 864th episode of the PokerNews Podcast, which is sponsored by the free-to-play WSOP App, Chad Holloway and Kyna England are joined by Connor Richards at Level 9 Studio to talk about a player who was stripped of their World Series of Poker (WSOP) gold bracelet and subsequently banned. Find out who and what happened here. They then talk about happenings thus far from the 2024 Pokerstars North American Poker Tour (NAPT) at Resorts World including Stephen Song winning the $25,500 Super High Roller, Will "The Thrill" Failla winning a tournament he didn't even mean to enter, and Kyna's experience in the NAPT Women's Event (plus her upcoming trip to London). Other topics discussed include Jason Koon becoming a PokerStars Ambassador, Chad's trip to Montreal where Michael Wang won the WPT Playground Championship, and the recent trend of shirtless winner photos, which was actually started back in 2010 by Pascal Lefrancois. PokerNews PA Ambassador Keith Becker then chats with NAPT Gold Pass winner Luis Rivera, Ethan “Rampage” Yau won a CSOP event, and Chad shares highlights from the Jeremy Renner Charity Poker Event at Venetian. Finally, learn about the new PokerNews Podcast contest to win a seat into the $5M Freeroll at WPT World Championship simply by watching and commenting on the trailer for new poker documentary ‘The Ultimate Stack'! The podcast has a new sponsor in the #1 free-to-play WSOP app, and as part of it, we run another "WSOP Replay" segment in which Chad reviews a famous poker hand through the lens of the WSOP App. Check it out and remember to use bonus code "POKERNEWS" if you download and play for an extra 1,000,000 in chips! A new PokerNews Podcast will drop weekly every Friday at 8a PT / 11a ET / 4p UK time. Remember to subscribe to our YouTube channel so you do not miss an episode! Time Stamps *Time | Topic* 00:11 | Welcome Kyna England & Connor Richards 00:24 | Francesco Garofalo stripped of $25K GGMillion$ SHR WSOP Online bracelet  07:00 | GGPoker's $500M acquisition of WSOP is finalized 08:50 | Sponsor: WSOP Free-to-Play App 09:55 | Kyna England going to England for Women's Festival 11:05 | 2024 NAPT Women's Event highlights 12:45 | Sheila Stimson wins NAPT Women's Event 13:20 | Gregor Sverko wins $550 Mystery Bounty title 14:20 | Will “The Thrill” Failla wins tournament he mistakenly entered 15:38 | Richard Bai wins $1,100 RunGood Open at NAPT 16:36 | Stephen Song ships NAPT $25,500 Super High Roller 18:00 | Favorite NAPT moments thus far 19:20 | Jason Koon new PokerStars Ambassador 19:40 | Chad's trip to Montreal's Playground 20:15 | Michael Wang wins WPT Playground Championship 22:17 | Kevin Rabichow beats Pascal Lefrancois to win WPT Playground High Roller 23:53 | Catching up w/ NAPT Gold Pass winner Luis Rivera 26:25 | Contest to win a seat into $5M Freeroll at WPT World Championship 28:29 | Trailer for new poker documentary ‘The Ultimate Stack' 30:27 | Highlights from the Jeremy Renner Charity Poker Event at Venetian 31:40 | Ethan “Rampage” Yau wins Charity Series of Poker (CSOP) event 32:47 | Upcoming CSOP Events this weekend[/TABLE]

Featuring perspectives from Dr Tycel Phillips and Dr Michael Wang, including the following topics: Introduction: Interface Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (0:00) Key Datasets — Overview and First-Line Therapy (7:16) Faculty Case Presentations — Dr Phillips (27:03) Key Datasets — Relapsed/Refractory Disease (35:40) Faculty Case Presentations — Dr Wang (48:06) CME information and select publications  

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma | Faculty Presentation — Michael Wang, MD CME information and select publications.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/BTKInhibitorsMCL24).

Drs. John Sweetenham and Marc Braunstein discuss practice-changing studies in hematologic malignancies that were featured at the 2024 ASCO Annual Meeting, including the ASC4FIRST trial in chronic myeloid leukemia and IMROZ and CARTITUDE-4 in multiple myeloma.  TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News Podcast. On today's episode, we'll be discussing practice-changing abstracts and other key advances in hematological malignancies that were featured at the 2024 ASCO Annual Meeting. Joining me for this discussion is an old friend, Dr. Marc Braunstein, a hematologist and oncologist from the NYU Langone Perlmutter Cancer Center.  Our full disclosures are available in the transcript of this episode. Marc, it's great to have you back on the podcast again. There were some important studies in the heme space at the Annual Meeting this year, and we're very pleased that you're able to share your takeaways.  Dr. Marc Braunstein: Thank you, John. It's great to be back again. Dr. John Sweetenham: Let's start out, Marc, with LBA6500. This abstract reports the primary results of the ASC4FIRST trial, and this was a trial comparing asciminib with investigator selected tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia. Could you tell us a little about the trial and how you think it's going to impact clinical practice? Dr. Marc Braunstein: Absolutely. So, asciminib is an oral tyrosine kinase of the ABL kinase domain. As we know in CML, the BCR-ABL translocation is characteristic of the disease, and asciminib is approved for chronic phase CML with a T315I resistance mutation or for patients who have received 2 or more prior lines of therapy. So the ASC4FIRST trial was a randomized trial of 405 patients with newly diagnosed chronic phase CML who are randomized one to one to receive either asciminib at 80 milligrams once daily, or investigator's choice of a first generation TKI imatinib or one of three second generation TKIs nilotinib, dasatinib, or bosutinib. The primary endpoint of the study was the major molecular response, or MMR, at 48 weeks. Pretty much, the study met its primary endpoint with a 67% rate of MMR at 48 weeks, with asciminib versus 49% in patients treated with the investigator's choice of TKI. And in addition, the major molecular remission or MMR of 4.5, which is a deep remission, those rates were higher as well, with asciminib versus investigator's choice at a rate of 39% versus 21% when comparing the groups. Furthermore, when we looked at toxicity, there were fewer grade 3 or higher adverse events, with the asciminib at 38% versus either 44% with the first generation, or 55% with the second generation TKI, and fewer discontinuations as well with asciminib.  So I think this abstract is practice-changing. I think it offers compelling data to use asciminib upfront for chronic phase CML. Those who don't agree with that sentiment might argue that we want to see longer term follow up. There's a planned follow-up at 96 weeks. We would want to see the rate of progression to acute myeloid leukemia and of course overall survival as well. But I think the abstract certainly shows an improvement in outcomes with asciminib versus our current array of TKIs. Dr. John Sweetenham: Yeah, I think it certainly is, at least at minimum, potentially practice changing. I agree with you. Just one question, and this may be a little bit speculative, but do you have any thoughts about treatment free survival with asciminib and how that might line up against some of the other TKIs? Dr. Marc Braunstein: Yeah, that's a great question. The abstract did not necessarily address that, patients were treated until progression, but we know that with the current landscape of TKIs, that in patients who have achieved a deep MR of 4 or 4.5 for at least 2 years who discontinue their TKI, the rate of relapse is about 50%. The current study, the ASC4FIRST, doesn't address that, but I think it's a really good question about whether, for those patients who have achieved a deep remission, whether they can eventually stop asciminib down the line. Dr. John Sweetenham: Yeah, I guess it's one of those ‘watch this space' things.  So we'll see how the data mature out. And let's move on to what I think is another potentially practice-changing study, at least in certain parts of the world. And that's [the] LBA7000 study in classical Hodgkin lymphoma. As you remember, this was a German Hodgkin lymphoma study group trial which looked at the tolerability and efficacy of a novel regimen, BrECADD versus eBEACOPP for patients with advanced stage classical Hodgkin lymphoma in their study, which is known as GHSG HD21. Can you give us your thoughts and take home messages from this trial? Dr. Marc Braunstein: Yeah, John, absolutely. So the German HD21 study is a phase 3 study of 1,500 patients with classical Hodgkin lymphoma. The majority were stage 3 or 4, 84%, that compared two regimens BEACOPP to BrECADD. The major difference between these 2 groups being that the newer BrECADD regimen swaps out bleomycin for brentuximab vedotin, which is an anti-CD30 antibody drug conjugate. Also, in the BrECADD regimen they eliminate vincristine that's incorporated into BEACOPP. Those are kind of the global differences between these 2 regimens. And when comparing these, they looked at the primary endpoint of progression-free survival. Of note, in this study there was a PET adjusted approach where if patients achieved interim PET negativity after 2 cycles, that was followed by an additional 2 cycles of their treatment as opposed to 4 cycles if they were PET positive after the initial 2 cycles of their respective treatment. And of note, there were similar rates of PET2 negativity between both arms, about 58% in both arms.  So at a median follow-up of 48 months, the 4-year progression-free survival was significantly better with the brentuximab containing BrECADD regimen at 94% versus 91% with a hazard ratio of 0.66. And the overall survival of the BrECADD arm was 98.6%, which is very high and impressive. The 4-year overall survival was similar between the arms at around 98%, but of note, there were fewer severe adverse events with BrECADD, the brentuximab containing arm versus BEACOPP at about 42% versus 59% and interestingly less peripheral neuropathy with the brentuximab containing BrECADD. So we're doing extremely well in treating advanced stage classical Hodgkin lymphoma. So the bar is set very high. But in this study, the rates of progression-free survival and overall survival are very impressive.  While these intensive regimens tend to be used outside of the U.S., there are several notable benefits of the study, including greater than 50% PET2 negativity and high rates of progression-free survival at 4 years. In discussing this abstract, it's worth noting that there are other competing regimens, if you want to call it that, that are more commonly used in the U.S. So the ECHELON-1 study looked at brentuximab AVD compared with ABVD with bleomycin and it was a 94% versus 89% 6-year overall survival rate favoring the brentuximab containing A+AVD regimen. And lastly, more recently, the SWOG S1826 study that hasn't been published but was presented in abstract form looked at nivolumab AVD versus brentuximab AVD at a median follow up of 12 months showed a progression-free survival of 94% versus 86%. And that study still has yet to be published and needs to mature. But both of those regimens are in the NCCN guidelines. So, we're definitely pushing the bar higher in terms of improving responses in treating advanced classical Hodgkin lymphoma. Dr. John Sweetenham: I think that there's no question that these results from BrECADD are very impressive. But I'm taken back to what I think has been a kind of philosophic discussion in Hodgkin lymphoma now for a number of years about balancing disease control and efficacy against the potential short-term and long-term toxicity of the regimens, particularly when you have very effective salvage therapies for those patients who may suffer a relapse. So I think that this is a discussion over whether you take a very intensive, upfront approach to Hodgkin lymphoma versus something that may be less and slightly less intensive. I suspect that's a discussion that's going to continue for a long time. I don't know what you feel, but my own feeling about this is that this study will likely have a major influence over treatment of Hodgkin lymphoma, particularly in western Europe. Less likely in the US.., I would think. I don't know what your thoughts about that are. Dr. Marc Braunstein: Well, it's a great question. In SWOG S1826, that study did include pediatric patients. In HD21, the median age was 31 and did not include pediatric patients. So I think we have to be selective in terms of fitness and which patients may be better suited for different regimens. But I think what all these studies show is certainly when we incorporate novel immunotherapies, whether it's brentuximab vedotin, nivolumab, we improve progression-free survival and even overall survival. Dr. John Sweetenham: Absolutely.  So let's shift gears now and take a look at Abstract 7500, the IMROZ study. This was the study of isatuximab, bortezomib, lenalidomide and dexamethasone versus VRD alone for transplant ineligible patients with newly diagnosed multiple myeloma. I know we discussed this in our preview podcast a few weeks back, Marc, but I just wonder now, having seen the data in more detail, what do you think of the important takeaways? And again, are we looking at a new standard of care? Dr. Marc Braunstein: You know, there are many standards of care in multiple myeloma, but we're always looking to make improvements on the regimens we have at our disposal. So, just to recap, IMROZ is a phase 3 randomized study of the anti-CD38 monoclonal antibody isatuximab with the backbone of bortezomib, lenalidomide, dexamethasone or VRD versus VRD alone, specifically, in transplant ineligible newly diagnosed multiple myeloma patients age less than 80. They studied 446 patients in this study, randomized 3 to 2 to Isa-VRD versus VRD alone, with the primary endpoint of progression free survival. Now, similar to other studies where they included a monoclonal antibody up front, the study met its primary endpoint of improving progression-free survival with the quad regimen containing the monoclonal antibody isatuximab versus VRD alone.  So what was interesting about the study, it's really the first of its kind to be presented that specifically looked at transplant ineligible patients, which is presumably a less fit or perhaps more frail population that wouldn't go on to consolidation with stem cell transplant. And in this study, the progression-free survival at 5 years was 63% versus 45%, clearly superior when you included isatuximab. And the rates of complete remission and MRD negativity were all significantly improved, too. However, that was also met with slightly more grade 3 or higher treatment emergent adverse events, 92% versus 84% in the control arm. There are also 11% grade 5 treatment emergent adverse events with the isatuximab group versus 5.5% with VRD alone. Although there was no major difference in treatment discontinuation. One small caveat worth noting, too, is that high-risk patients in this study, when presented at ASCO, did not necessarily show a difference in benefit, although there wasn't necessarily a detriment either.  So, John, I think that clearly quadruplet regimens are superior in outcomes of efficacy to triplets, even in transplant-ineligible patients. But I think we have to tailor these treatments to individual patients because I think when it comes to transplant-ineligible patients, it's a spectrum of patients who may be more or less fit for quad regimens versus triplet regimens. It's also worth noting, though, that in this study, the patients are really only getting a quad regimen for 4 cycles. They get their Isa-VRD, and then you drop the bortezomib.  So when we think about quads, it's not that they're getting the quad regimen indefinitely, it's really for the induction cycles. But still, I think we have to be aware of potential safety issues. Dr. John Sweetenham: Okay, great. And let's stay on the theme of multiple myeloma, Marc, and talk a little bit about Abstract 7504, which was a subgroup analysis of the CARTITUDE-4 study. This is a report on the use of ciltacabtagene autoleucel versus standard of care in patients with functional high risk multiple myeloma. Can you give us your thoughts on this and maybe put it into a bit of context for us?  Dr. Marc Braunstein: Absolutely, John. It's really a great time to be in the field of multiple myeloma. We're making tremendous progress, but when we think about one of the unmet needs, it's just consistently the high-risk patients who have shorter responses and are at higher risk for poorer outcomes. Just to review, cilta-cel is one of the 2 available anti-BCMA CAR T-cell products available for the treatment of relapsed or refractory multiple myeloma. Very recently, the FDA approved cilta-cel for lenalidomide refractory patients after 2 or more prior lines of therapy based on the CARTITUDE-4 study, which was published by San-Miguel and colleagues in New England Journal of Medicine in July 2023. And that study randomized 419 patients with multiple myeloma with 1 to 3 prior lines of therapy to receive either cilta-cel or physician's choice of standard of care, which was either 1 of 2 triplet regimens, a pomalidomide, bortezomib, dexamethasone or daratumumab, pomalidomide and dexamethasone. It's worth noting that about 25% of the patients in the CARTITUDE-4 study had prior anti-CD38 antibody treatment previously and the carfilzomib was not included in one of the standard-of-care arms, and we know that those regimens containing carfilzomib do increase survival in relapsed myeloma.  Nevertheless, the primary outcome of progression-free survival was not reached in the CAR T-cell arm versus 11.8 months in the standard-of-care arm, with a significant reduction in progression of 74%. So clearly a positive study and CAR T-cell therapy is included in the NCCN guidelines for patients who have an early relapse from their myeloma. The current abstract by Costa et al focused specifically on a subgroup of 79 patients from CARTITUDE-4 in second line of treatment and looked at what they called functional high-risk myeloma, defined as progression of disease within 18 months of initial treatment or after stem cell transplant. Again, the study showed a retained benefit of cilta-cel with significant improvement in progression-free survival either not reached or 12 months with the control standard of care arm, as well as complete remission rate and rates of MRD negativity of 65% versus 10% in the control.  The overall survival outcome was still immature and not presented. Nevertheless, cilta-cel is clearly superior to standard-of-care triplet regimens. I think that for patients with high risk, they clearly derive a benefit from CAR T-cell therapy if they have short progression-free survival after initial therapy.  Dr. John Sweetenham: Thanks, Marc. So let's round this out by talking about another area of unmet need, I guess in a way in a difficult to treat patient group. And that's Abstract 7007, the SYMPATICO study. This is a study which looks at the efficacy and safety of ibrutinib and venetoclax in patients with mantle cell lymphoma who had a mutated TP53. Can you just briefly review this for us and tell us what you think we should be taking away from this studys? Dr. Marc Braunstein: So, mantle cell lymphoma typically has an aggressive behavior, but the subgroup of patients with a P53 mutation tend to have the poorest outcomes and do represent an area of unmet need. Although BTK inhibitors are making important improvements in mantle cell lymphoma, they have yet to be approved in newly diagnosed mantle cell lymphoma. Acalibutinib and zanubrutinib are FDA-approved BTK inhibitors for previously treated mantle cell lymphoma. Ibrutinib was withdrawn from the market in the U.S. for mantle cell lymphoma. Dr. Michael Wang's group presented late-breaking data from the phase 3 SYMPATICO trial at ASH 2023, in which 267 patients with relapsed refractory mantle cell lymphoma were randomized to receive either ibrutinib plus the BCL2 inhibitor venetoclax or ibrutinib plus placebo after 1 to 5 prior lines of therapy. And that study showed a 32 versus 22 months progression-free survival at a median follow up of 51 months. The current abstract, also by Dr. Wang and colleagues, looked at the subgroup of patients who had a P53 mutation and included an open label cohort of 44 patients in the first line of treatment and a relapse refractory cohort of 75 patients, and compared this subgroup of patients with P53 mutation to those without. When we look at the outcomes, the patients who did not have a P53 mutation clearly did better in terms of progression-free survival being not reached in first-line treatment compared to 22 months progression-free survival in those patients with first-line [treatment] with a P53 mutation. As well as in the relapsed refractory setting, the PFS without the P53 mutation was 47 months versus 21 months with the mutation. However, when you look at these patients treated with ibrutinib and venetoclax comparing whether they got treated in first line or the relapse refractory setting, the overall response rates are very similar at about 80% to 90% and the CR rates were very similar at about 55% to 58%, which to me suggests that although patients with P53 mutation do worse than those without it, whether they're treated in the first-line or the relapse setting with this combination of venetoclax, they tend to do somewhat similar, suggesting that you can overcome resistance to prior therapy in the relapse setting. So I think further data are certainly warranted to explore the role of combination therapies that include novel agents such as BTK inhibitors in the first line setting.  It's worth noting that the TRIANGLE study was recently published, and this study looked at including ibrutinib at various phases, including at induction in combination with intensive chemotherapy and during the maintenance phase. And that study showed encouraging outcomes in patients who received ibrutinib even without stem cell transplant compared to those who received stem cell transplant. So the role of BTKIs in mantle cell lymphoma is certainly evolving, and I think it offers a very effective intervention without the same kind of toxicities we see with cytotoxic chemotherapy that's traditionally used in mantle cell lymphoma. But I think the subgroup of patients with P53 mutation in this disease still represent an area of unmet need that unfortunately have worse outcomes. But novel agents may be able to overcome some of those adverse outcomes. Dr. John Sweetenham: Yeah, I agree. I think these are intriguing data, and obviously it needs more follow-up and probably more prospective studies. But nevertheless, I think there are some signals there for sure that need to be followed up on.  Marc, as always, it's great to have your insights on key advances in the heme space from ASCO. An important year this year, and we really appreciate your time and effort in sharing with us your thoughts on what we've learned this year. So thank you as always. Dr. Marc Braunstein: My pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstract discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. Marc Braunstein  @docbraunstein    Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS   

Dr. John Sweetenham and Dr. Marc Braunstein look ahead at key abstracts across the spectrum of hematologic malignancies that will be presented at the 2024 ASCO Annual Meeting, including the OPTIC trial in chronic myeloid leukemia, treatment options for transplant-ineligible patients with multiple myeloma, and the 7-year analysis of the ECHELON-1 trial in classical Hodgkin lymphoma. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and the host of the ASCO Daily News Podcast. I'm delighted to be joined again this year by Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center in New York. We're going to be discussing some of the key abstracts in hematologic malignancies that will be featured at the 2024 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode, and disclosures of all guests on the podcast are available at asco.org/DNpod.  Marc, it's great to have you back on the podcast. Dr. Marc Braunstein: It's a pleasure to be back, John.  Dr. John Sweetenham: There are some exciting abstracts to be presented at this year's meeting, and I would like to begin, if we can, with Abstract 6501. As you know, this reports the four-year results from the OPTIC trial of ponatinib in patients with chronic-phase CML and the T315I mutation. Can you tell us about the trial and about these latest follow-up results? Dr. Marc Braunstein: Sure. Well, we've made tremendous progress in managing patients with CML in the past two decades using these oral tyrosine kinase inhibitors such as ponatinib. Ponatinib is a third-generation TKI that has activity in both Philadelphia-positive ALL as well as CML, and can overcome the resistance mutation you mentioned, called the T315I mutation, which is sometimes found following prior TKI therapy. The OPTIC study is a multicenter phase 2 randomized study of various doses of ponatinib in 283 chronic phase CML patients who had received 2 or more prior lines of therapy or those who had the presence of a T315I mutation, with the current analysis examining the major remission at 48 months, PFS, as well as OS. Of note, in this study, after patients have achieved a major remission with a transcript level of 1% or less, the study allowed for dose reduction of ponatinib from the original dose of either 45 milligrams or 30 milligrams to a reduced dose of 15 milligrams.  So, when we look at the results, we find that the patients who had the highest overall response rates and higher rates of molecular remission were those who received the 45-milligram dose. And remember, these patients were allowed to be dose-reduced to the 15-milligram dose once they achieved a molecular remission of 1% or less. In addition, the rates of overall survival were highest in the 45-milligram dose as well. When looking at the T315I subgroup, the rates of molecular remission, the depth of remission, and the rates of progression-free survival, in general, were lower in that subgroup, but still higher in the 45-milligram dose than the 35- milligram dose.  Furthermore, when looking at the rates of treatment-emergent adverse events leading to discontinuation, they were 8% in the 45-milligram dose compared to 14% in the 30-milligram dose and 5% in the patients who only received the 15-milligram dose. The authors have concluded that the 45-milligram dose, with the potential to be reduced to 15 milligrams after achieving 1% or less of the BCR-ABL transcript level, seems to be the right balance between efficacy and safety.  Dr. John Sweetenham: Thanks, Marc. In the longer term, do you think that this study will, in any way, affect the position of ponatinib in the treatment algorithm for CML? Is it going to remain as a second or third-line option, or do you think there's any chance it will be moved up? Dr. Marc Braunstein: Well, that's a great question. There are other TKIs, such as asciminib, that also target the T315I mutation, and that mutation tends to develop after prior first-line or second-line TKI therapy. But given its activity in both ALL and CML, I think it's certainly reasonable to expect that ponatinib will be used in earlier lines of therapy given its efficacy in later lines. Dr. John Sweetenham: Let's change gears and move the focus to acute myeloid leukemia. There has been a lot of discussion around frailty in many different malignancies, but the impact of frailty on outcomes in AML is maybe something that hasn't been quite so well studied. In Abstract 6506, investigators did a population-based study in Ontario, Canada, that assessed the patient's frailty risk and the impact that might have on outcomes. What are your takeaways from this study, and how do you think these data will help optimize treatment decisions?  Dr. Marc Braunstein: Yeah, I'm glad we're talking about this abstract John, because frailty scores are increasingly being used in hematologic malignancies to help guide goals and intensity of care. And as opposed to using age or performance status alone, these composite frailty assessment tools, such as the MFI tool that they used in this particular study, take into account multiple variables that are both physiologic, such as the patient's comorbidities, as well as social, and what kind of support system do they have, and things of that nature. And that accounts for their overall fitness. So, in this retrospective cohort study that was a population-based study in Ontario between 2006 and 2021, they looked at 5,450 patients retrospectively with acute leukemia and grouped those patients into 3 categories based on this frailty index. Patients who are either fit, somewhere in the middle between fit or frail, which they call pre-frail, or frail. And they looked at outcomes such as overall survival, comparing patients who got intensive chemotherapy regimens for induction or those who got non-intensive therapy for induction. Patients in either group could have been assigned to either fit, pre-frail, or frail although there are much more fit patients than those who got intensive induction.  And so, looking at their findings, it was noted that patients who were in the frail category, not entirely unexpectedly, had lower overall survival when compared to those who were fit or pre-frail. I think the value of a study like this is not just to highlight the benefit of frailty scores to help predict which patients may ultimately have a shorter survival, but also to help potentially guide which patients may be more suitable for intensive versus less intensive induction. I will note that this study was conducted in an era where we didn't have the same sorts of less intensive induction that are very effective in less fit patients, such as the combination of azacytidine and venetoclax, which is commonly used in less fit patients nowadays. So, the study may encompass patients who didn't have access to that therapy because it wasn't available during that time. But I think it still, overall, does highlight the fact that assessing fitness or frailty in acute myeloid leukemia is important for predictive value. Dr. John Sweetenham: I agree. Marc, I don't know what your thoughts are on this, but it goes either way. I mean, I think that, if I remember the numbers correctly, 25% of fit patients received non-intensive therapy. So, is there a missed opportunity there for that group of patients who actually may have tolerated the intensive therapy but it was never offered? Dr. Marc Braunstein: That's an excellent point, John, and I think that highlights the importance of frailty indices because they take into account much more than one particular factor, or even just a subjective assessment of the patient in real time when they're first presenting. And they may have disease-specific features that are decreasing, say one element of their assessment such as their performance status. So, really taking these composite fitness scores into account may actually allow you to escalate therapy in a patient who may actually be fit but maybe perceived as less fit when they present. Dr. John Sweetenham: Yeah. So, I think, as you mentioned, there are better treatment options out there now maybe than there were at the time this study was conducted. Nevertheless, there may still be that opportunity for more intensive therapy for some of these patients when they are more holistically assessed.  Let's move on and switch gears once again and talk about a study in multiple myeloma, the so-called IMROZ study, which is Abstract 7500. So, this is a study looking at treatment options for transplant-ineligible patients with newly diagnosed multiple myeloma. Some of these patients may not have a chance for subsequent therapy if they are not eligible for transplant. What are your thoughts on this study? Do you think we're closer to a new standard of care for patients who are not going to proceed to an autologous stem cell transplant?  Dr. Marc Braunstein: It seems like every year there's a new standard of care for newly diagnosed multiple myeloma because there's so much data emerging, which is just wonderful. So, I think as background, at the 2023 ASH meeting, the IsKia study was presented, which is a randomized phase 3 study in newly diagnosed transplant-eligible patients. And that was using isatuximab with carfilzomib, lenalidomide, and dexamethasone upfront and that study did show a benefit in terms of reducing minimal residual disease compared to carfilzomib, lenalidomide, and dexamethasone alone. But that study was looking at fit newly diagnosed patients who were going on to stem cell transplant. Right now, the standard of care for patients who are not eligible for transplant is generally to use a 2 or 3-drug regimen, such as daratumumab, lenalidomide, and dexamethasone, based on the phase 3 MAYA study. But this study is really unique in that it looks at using a quadruplet regimen in patients who are transplant ineligible or not intended to go for transplant.  So, the phase 3 IMROZ study was a randomized study of 446 patients that compared isatuximab, bortezomib, lenalidomide, and dexamethasone to bortezomib, lenalidomide, and dexamethasone alone. So, a quad versus a triplet regimen. The primary endpoint in this study was progression-free survival, but they also looked at secondary endpoints, such as complete response rate and minimal residual disease negativity.   Just to quickly highlight the results and then discuss the standard of care, the median duration of treatment in this study was 53 months in the quad regimen and 31 months in the control arm. At a median follow-up of about 60 months, the progression-free survival was not reached with the quad regimen versus 54 months in the triplet, and that was a significant difference. In addition, the safety profile was pretty much consistent with the class, there were a bit more grade three or higher treatment-emergent adverse events with the ESA-containing regimen, 92% versus 84%, but no difference in adverse events leading to discontinuation in either arm.   So, this study is certainly compelling in terms of using quadruplet-based regimens that contain an anti-CD38 monoclonal antibody for newly diagnosed patients who are not intended to undergo transplant. I think at the meeting, I will be interested to see the patient population that was included. Patients who are over the age of 80, for example, are excluded. So, I would like to know more about their fitness level and performance status. But I think it's clear, John, that using quad regimens over triplet regimens is just consistently superior in terms of efficacy outcomes. Dr. John Sweetenham: Right. I guess that, even though maybe we can't focus on the specific agents right now, it looks as if quad regimens are going to be the standard of care regimens for the future in this group. Do you think that is fair?  Dr. Marc Braunstein: Very likely. Dr. John Sweetenham: Absolutely. Well, that's a pretty challenging group of patients.   And so to move on again, let's talk about another, perhaps equally challenging group - patients with mantle cell lymphoma, particularly those who carry certain mutations. The so-called SYMPATICO study, which is reported in Abstract 7007, presents data on the efficacy and safety of ibrutinib and venetoclax in patients with mantle cell lymphoma who carry a TP53 mutation. We know that this mutation confers a high risk of early progressive disease and poorer outcomes when these patients are treated with standard chemoimmunotherapy for mantle cell. Trials to date have been limited to small single-arm studies. Can you tell us a little bit about this study and the outcomes and what you think it means for the future?  Dr. Marc Braunstein: As a background, although BTK inhibitors such as ibrutinib have yet to be approved for newly diagnosed mantle cell lymphoma, acalabrutinib and zanubrutinib, which are second-generation BTK inhibitors, are FDA-approved for previously treated mantle cell lymphoma. Ibrutinib was withdrawn from the market. The lead author of this abstract, Dr. Michael Wang, had presented a late-breaking data from the phase 3 SYMPATICO trial at ASH last year, in which 267 patients with relapsed or refractory mantle cell lymphoma after one to five prior lines of therapy were randomized to receive the combination of ibrutinib plus the BCL-2 inhibitor venetoclax or ibrutinib plus placebo. That study showed there was a 32 versus 22-month progression-free survival with a hazard ratio of 0.65 at a median follow-up of 51 months, indicating the PFS benefit of the combination of ibrutinib and venetoclax compared to ibrutinib with placebo.   So that leads us to this subgroup analysis in the current study being presented at ASCO, in which they looked at a subgroup of patients with mantle cell lymphoma who are at very high risk for treatment failure and early relapse - those are patients who have a mutation in TP53, which again is high risk for treatment failure. This abstract examined an open-label cohort of 44 first-line patients, as well as 75 patients who were in the relapse/refractory cohort, and compared to patients who either did or did not have the P53 mutation. When we look at the progression-free survival outcomes, the median progression-free survival in the first-line cohort of patients who did not have a P53 mutation was not reached, whereas those with the P53 mutation had a median progression-free survival of 22 months, which is still meaningful but still less than those who did not have a P53 mutation. Which again is not entirely unexpected. But the overall response rate of the combination of ibrutinib and venetoclax was very high at 90%, and the median duration of response was about 21 months.  Now comparing this to the relapse/refractory cohort, in those without a P53 mutation, the progression-free survival of the combination of ibrutinib and venetoclax was about 47 months versus those who don't have the P53 mutation was about 21 months with an overall response rate of 80%. I think one takeaway looking at this comparison of the first-line and relapse/refractory setting is that patients seem to do very similar in terms of overall response rate and progression-free survival, whether they were in the first line or in the later lines of treatment if they had the P53 mutation, which says that the combination of ibrutinib and venetoclax is effective no matter which phase of the disease the patient might be in, indicating its overall activity and being strong.    Dr. John Sweetenham: Yeah, I thought that was an interesting observation, actually, how similar the outcomes were in those two groups.  Dr. Marc Braunstein: No, I agree. And I think although patients with TP53 mutations did comparatively worse than those without the mutation according to progression-free survival, overall response rate, or complete remission rates, they did seem to be similar whether a patient was in first-line or relapsed refractory if they were P53 mutant and were treated with this combination. So, I think we need further data in the first line, such as the data that's awaiting publication from the TRIANGLE study, which is examining upfront ibrutinib. But certainly, BTK inhibitors have significant activity in either the first line or the relapse setting of mantle cell lymphoma.  Dr. John Sweetenham: Great. Thanks, Marc.  Let's wind up with one more abstract, and this is Abstract 7053. It's a 7-year analysis of the so-called ECHELON-1 study. This was a study comparing the standard of care, ABVD, with the same regimen with bleomycin substituted by brentuximab vedotin for patients with previously untreated advanced-stage classical Hodgkin lymphoma. The study at the time it was originally reported, resulted in a significant practice change in the first-line therapy of Hodgkin's lymphoma. We now have mature follow-up. What are your take-homes from this study? Dr. Marc Braunstein: The ECHELON-1 study has certainly been a practice-changing clinical trial where, as you said, brentuximab with the backbone of AVD was compared to ABVD, which was the prior standard. And this was examined in newly diagnosed patients with classical Hodgkin lymphoma who were at advanced-stage, stage 3 or 4. The publication, first of the progression-free survival, and more recently, in the New England Journal of Medicine in 2022, where we saw the 6-year overall survival was 94% with the brentuximab-containing arm versus 89% in the control arm, established the brentuximab AVD, or otherwise called AAVD, as the standard of care in advanced stage newly diagnosed classical Hodgkin lymphoma. The current study is now reporting 7-year follow-up on about 1,300 randomized patients who were enrolled in this impressive study.   Though at a median follow-up of 89 months now, the 7-year overall survival was quite similar, 94% versus 89%, again favoring the brentuximab-containing arm. In particular, this was driven by patients who had stage 4 disease or those patients who were aged less than 60 in subgroup analyses. So, what I take away from this abstract in the 7-year follow-up of the ECHELON-1 is that brentuximab with AVD remains the standard of care for previously untreated advanced-stage classical Hodgkin lymphoma. It is worth noting that the SWOG S1826 study that was presented at ASCO last year compared nivolumab with AVD compared to brentuximab AVD and did show a slight PFS advantage of 94% versus 86% with nivolumab AVD. Obviously, these were different studies with different patient populations enrolled, so we're really just cross-comparing different studies. But I think brentuximab AVD, given the survival benefit that is retained now at seven years in the current abstract, still remains the standard of care for advanced-stage classical Hodgkin lymphoma. The role of immune checkpoint inhibitors like nivolumab is making headway in terms of treating newly diagnosed patients as well. Dr. John Sweetenham: Yeah, thanks, Marc. I mean, one of the observations that I thought was of interest in this study was the outcome for patients who were PET-2 positive, when you compare AAVD and ABVD. It does seem as if even in those patients who are PET-2 positive, having had AAVD, they still apparently have a better outcome than those who received ABVD in that situation who were PET-2 positive. So, I think that's another interesting observation. I'm not quite sure what it means, except speaking to the overall superior efficacy of that regimen. Dr. Marc Braunstein: You make a great point, John, because it's worth noting that in ECHELON-1, a PET scan was done after cycle 2, but the study was not PET-adapted. So even if you had a positive PET, you continued for the full six cycles of treatment. But PET-2 status is often used in various studies of Hodgkin lymphoma to guide whether to give additional cycles or escalate therapy. So, I think the benefit of presenting those subgroups is that even if you were PET-2 positive, you still did better by continuing on the brentuximab-containing regimen. Dr. John Sweetenham: Yeah, exactly. I mean, the other important takeaway message, I think, is that the outcome for patients with advanced Hodgkin lymphoma seems to continue to steadily improve, which is great news and also really remarkable. And I'm excited to see there may be some additional data presented at one of the late-breaking abstracts in this year's meeting, so it will truly be interesting to see what that shows us as well.  Dr. Marc Braunstein: Incredible. Dr. John Sweetenham: Well, Marc, as always, thank you for sharing your insights with us today on the ASCO Daily News Podcast. We look forward very much to hearing the updated data from these abstracts at the meeting.  Dr. Marc Braunstein: As do I and thank you so much for inviting me again.  Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest: Dr. Marc Braunstein @docbraunstein   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures:  Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness   Dr. Marc Braunstein: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp Speakers' Bureau: Janssen Oncology Research Funding (Institution): Janssen, Celgene/BMS

This week, Michael Wang, co-CEO of Ispire Technology, joins the Cannabis Equipment News podcast to discuss how he helped build a multi-million-dollar vaping empire by solving pain points for cannabis brands and operators. Please make sure to like, subscribe and share the podcast. You could also help us out by giving the podcast a positive review. Finally, to email the podcast or suggest a potential guest, you can reach David Mantey at David@cannabisequipmentnews.com.Click here to subscribe to our newsletter.

Blunt Business welcomes Michael Wang, Co-CEO and CFO with ISPIRE, a company specializing in e-cigarettes and cannabis vaping products. Discussions included collaborations with Hidden Hills, new device launches like Switch One, and partnerships with Burna Boy. Safety measures, regulatory challenges, and quality assurance with ISO and GMP certifications were highlighted. Market trends indicated a rise in vaping products in cannabis sales, with projections of vaping reaching up to 50% of retail sales. Strategic global expansion plans were explored through partnerships outside North America. I Spire's role as an innovator in hardware design for over 400 brands without direct branding association was emphasized, showcasing their forward-thinking strategies for staying ahead in the industry.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this exclusive interview from the NGA show, Michael Wang, CEO, and Vaughn Roller, Chief Business Officer at SIRL, reveal how their cutting-edge retail technology is transforming the way retailers track shopping journeys and optimize store operations. SIRL's real-time location system leverages low-cost tracking tags and wireless infrastructure to achieve an unprecedented 3-foot accuracy and 1-second latency, effectively creating a "physical search engine" for retail. Discover how SIRL's solution empowers retailers to enhance shopper privacy while tapping into the potential of retail media networks and in-store advertising. Learn about the significant ROI and revenue opportunities generated by this technology, as well as its ability to streamline merchandising optimization and shopper behavior clustering. With its easy deployment and reliance on Bluetooth Low Energy, SIRL is poised to revolutionize the retail landscape. And thank you to the VusionGroup for making our coverage of NGA possible! #SIRL #retailtechnology #indoorpositioning #realtimeloca ionsystem #shoppingjourneytracking #lowcosttrackingtags #wirelessinfrastructure #3footaccuracy #1secondlatency #physicalsearchengine #shopperprivacy #retailmedianetworks #instoreadvertising #improvedstoreoperations #ROI #revenueopportunities #easydeployment #merchandisingoptimization #shopperbehaviorclustering #BluetoothLowEnergy

How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center in Houston, told the conference how a combination of two targeted drugs—ibrutinib and venetoclax—improved outcomes.

National Ethanol Conference wrap up  The Renewable Fuels Association was pleased to welcome USDA Secretary Tom Vilsack to the NEC this year, as well as Doug McKalip, Chief Agricultural Negotiator in the Office of the United States Trade Representative. This edition of the Ethanol Report includes comments from both of them, as well as RFA President and CEO Geoff Cooper, RFA Chairman Erik Huschitt of Badger State Ethanol, Dr. Michael Wang with Argonne National Laboratory, and RFA Senior VP, Industry Relations & Market Development Robert White.

Although strides have been made with Bruton tyrosine kinase (BTK) inhibitors and CAR-T cell therapy, relapse and resistance remain significant hurdles in treating patients with mantle cell lymphoma (MCL). The Lymphoma Research Foundation's 2023 MCL Scientific Consortium and Workshop addressed these complexities, aiming to dissect the intricate biology of MCL and propel progress towards a cure. CancerNetwork® spoke with leaders in the MCL field to better understand the aim of the consortium and the advancements they hope to see in the space. The journal ONCOLOGY® published these findings in the February 2024 issue. The interviews included Elias Campo, MD, PhD, research director and professor of anatomic pathology at the Hospital Clinic of the University of Barcelona; Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas, MD Anderson Cancer Center; Martin Dreyling, MD, PhD, professor of Medicine in the Department of Medicine and head of the Medical Clinic 3 at the University of Munich-Grosshadern in Germany; and Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris Professor and division chief in the Division of Hematology at the University of Nebraska Medical Center and coeditor in chief of ONCOLOGY.  The consortium touched on t(11;14), which dysregulates cyclin D1 and fuels uncontrolled cell growth. Additionally, research presented at the consortium revealed other molecular pathways contributing to treatment resistance and relapse, highlighting the heterogeneous nature of the disease. This heterogeneity underscored the need for personalized treatment strategies and biomarker-based prognostics, a notion further emphasized by multiple findings on the predictive value of specific gene mutations. Beyond understanding the inner workings of MCL, presentations also focused on novel therapeutic avenues. Specifically, there were encouraging data on the potential of next-generation BTK inhibitors including acalabrutinib (Calquence) to overcome resistance. Challenges such as the limitations of current risk stratification models remain, underscoring the need for robust biomarkers to guide early interventions and optimize treatment selection. Additionally, the consortium featured a discussion on addressing a lack of diversity in clinical trial populations, which may help increase treatment access for those with various medical conditions. “…The patient population that has a disease is not always [represented] in the clinical trials. That's why it's important to be able to have a diversity of patients in clinical trials: to test these new therapies because [patients] may have other medical conditions that would change the outcome of trials and not be necessarily representative of the entire patient population with that disease,” Vose said. “It's important to try to advance the treatment of a very diverse patient population through these clinical trial mechanisms.”

This week's episode features two neurosurgeons, Dr. Michael Wang, professor at the University of Miami Miller School of Medicine, and Dr. JP Kolcun, PGY 5 Neurosurgery resident at RUSH University Medical Center in Chicago. Here, they and Dr. Scott Sigman discuss the educational path to becoming a neurosurgeon, the differences between brain surgeons, spine surgeons, and orthopedic surgeons, their popular neurosurgery podcast, and more.

“Therapies are improving dramatically” in mantle cell lymphoma (MCL), according to Michael Wang, MD, professor in the department of lymphoma/myeloma, division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston. Dr. Wang presented updates on major advances in MCL at the recent Society of Hematologic Oncology (SOHO) annual meeting. Here, he speaks with Bob Figlin, MD, the Steven Spielberg family chair in hematology-oncology at Cedars-Sinai Cancer Center in Los Angeles, about which promising regimens from recent studies are most appropriate for certain age groups. Dr. Wang and Dr. Figlin also discuss common challenges when approaching newly diagnosed patients, as well as how to process the “explosion” of new information in MCL.

Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics: Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00) Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36) Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14) Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16) Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23) CME information and select publications

Featuring perspectives from Dr Michael Wang, including the following topics: Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00) First- and second-line therapy approaches for MCL (7:26) Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who develops severe headaches (10:21) Current role of ibrutinib in the treatment of MCL; use of single-agent venetoclax and of zanubrutinib in the treatment algorithm (14:59) Case: A 68-year-old man presenting with an enlarged spleen, no lymphadenopathy and a white blood cell count of 300,000 is diagnosed with MCL (17:48) Case: A 71-year-old man with multiregimen-relapsed, nodular type MCL presents with lymphadenopathy and a 3-cm tumor near the mediastinum (22:38) Patient selection for chimeric antigen receptor T-cell therapy (25:59) Novel and investigational therapeutic approaches for MCL (30:11) Treatment approaches for other histological variants of MCL (39:00) CME information and select publications

Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.

Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love. CME information and select publications here (https://researchtopractice.com/OncologyTodayBTKInhibitorsMCL23).

On this episode, we check out the latest book and publishing news in Asian American literature for our February 2023 mid-month check-in, including some major updates from the Harper Collins Union strike and some highlights from the ALA awards.New books and authors mentioned in our publishing news:Say You'll Be Mine by Naina KumarPangu's Shadow by Karen BaoBridge Across the Sky by Freeman NgBecoming Boba by Joanna Ho; illust by Amber RenHelga by Catherine YuThe Fetishist by Katherine MinThe Jade Bracelet by Hà Dinh; illust by Yong Ling KangWhen the Sky Is Deepest Blue by Clare OsongcoLeif's Gift written by Michael Wang; illust by Lenny WenWhat Color Is the Baby? by Harshini Vankineni; illust by Neha Rawat BattishDon't forget show support to the ongoing HarperCollins Union Strike by supporting their hardship fund at https://givebutter.com/HCPstrike*Support the podcast by purchasing books at our bookshop *Follow our hosts:Reera Yoo (@reeraboo)Marvin Yueh (@marvinyueh)Follow us:FacebookTwitterGoodreads GroupThe Books & Boba February 2023 pick is The Charmed List by Julie AbeThis podcast is part of Potluck: An Asian American Podcast CollectiveMentioned in this episode:Shoes Off: A Sexy Asians Podcast from WBEZIf you're looking for a new Asian American centric podcast, check out Shoes Off: A Sexy Asians Podcast from WBEZ Chicago: Asians have long been ignored, fetishized or made the butt of the joke in America. Shoes Off: A Sexy Asians Podcast wants to put that to rest. Each week, we celebrate badass Asians who are making a mark on pop culture and entertainment. Co-hosts Esther Yoon-Ji Kang and Susie An hang out with trailblazers in comedy, film, music and other fields—inviting them to reflect on their identities and redefine “sexy” on their own terms.Shoes Off: A Sexy Asians Podcast

Today, I'm excited to talk with impact investor and investment industry veteran H. Perry Boyle. Perry's had a long and storied career in the financial world, but the first thing I wanted to know about was his hiring of Prometheus Founder and CEO Michael Wang as a Senior Analyst at the legendary hedge fund SAC Capital. Between 2004 and 2020, Perry held several positions at SAC and Point72. As SAC's Director of Research, Perry's job was to change the culture, which he did—in part—by creating a curriculum for analysts and making portfolio managers stakeholders in their future success. Steve Cohen's SAC Capital is the inspiration for the Showtime series “Billions." So I asked Perry to describe the evolution of the firm's culture and the impact of having a psychologist on staff to optimize traders' performance. A little later, Perry tells me the "secret” of running a long/short portfolio and lays out his thoughts on the increasing scarcity of alpha. Lastly, Perry talks about the journey that took him from Point72 to climbing his “second mountain” —becoming chairman of the BOMA Project, a poverty graduation program for women, youth, and displaced persons in East Africa.Links MentionedThe BOMA ProjectH. Perry Boyle | LinkedInFollow UsLearn about PrometheusSubscribe to Prometheus Decoded on Apple Podcasts or SpotifyInstagramTwitterFacebook

Today's episode is an exceptional one. Some of the world's most interesting financial professionals review 2022 and share their predictions for the year ahead. Host Ryan Pallotta is joined by JAG Capital's Josh Goltry, Blue Duck Capital's Alex Beinfield, Wall Street veteran Eric Rosen and Prometheus Founder and CEO Michael Wang. The result is a rollicking hour and change of roasts and —a heaping helping of insight into how these professionals navigated a tumultuous 12 months and how they plan to thrive in 2023. Personal wins and losses are shared, predictions are proffered and challenged, statistics are interpreted, theses are scrutinized, strategies are discussed, heroes are lionized, villains are denounced, and a lot of laughs are had along the way.Check out what these pros are saying on the Prometheus app for free using the links below! Eric Rosen https://app.prometheusalts.com/profil... https://substack.com/profile/34844298... https://twitter.com/ericrosenreport/ Alex Beinfield https://app.prometheusalts.com/profil... Josh Goltry https://app.prometheusalts.com/profil... Prometheus website: https://prometheusalts.com/ iOS App: http://apple.co/3C9bPNY Web App: http://app.prometheusalts.com Studio Prometheus: https://studio.prometheusalts.com/ Podcasts Prometheus Decoded: https://apple.co/3hSIxvx Currently by Studio Prometheus: https://apple.co/3WuF4SX

In episode #3 of the Steez podcast, we talk about FinTok, and why Gen Zers are getting their financial education from social media. Our host, Rebecca Cohen is joined by Michael Wang, founder, and CEO of Prometheus, Jeff Frommer, Chief Content Officer at MoneyLion, and Michael Borough founder of Altro.

Disclosure: Opinions expressed in this podcast are meant for informational purposes only and should not be considered a recommendation or investment advice. All investments involve risk. Past performance does not guarantee future results. Securities products and services offered in the Prometheus Marketplace are private placements only sold to accredited investors. Private placements, sometimes referred to as alternative investments, carry a high degree of risk, including the potential loss of your entire investment, and are not suitable for all investors. For a more detailed disclosure, including Prometheus's conflicts of interest, visit: https://www.prometheusalts.com/legals/podcast-disclosure Our second investment idea event encapsulates Prometheus' primary goal: opening up investing in alternative investments—hedge funds, venture capital, private equity, etc.—to more people, giving them access to the same opportunities that institutions and family offices have enjoyed for decades. Today, Prometheus CEO and hedge fund veteran Michael Wang will be talking with: Jose Torres from Lokoya Capital Management Andrew Cowen from Brean Asset Management These incredible guests are brimming with insights that may impact how you think about investing forever.

Today Ryan Pallotta is talking with a very special guest, Prometheus Founder and CEO Michael Wang. Mike's an award-winning hedge fund veteran. An alum of Steve Cohen's legendary SAC Capital, Wang contributed to Tourbillon Capital Partners' early success before winning accolades as Cypress Funds' portfolio manager and co-managing partner. Mike created Prometheus around his strong belief that everyone should have access to information and investment opportunities that, historically, have only been accessible to a select few.  This amazing podcast covers a lot of ground. Mike begins by describing the nascent trend of fund managers creating content to grow their audience and raise capital at scale and how he created Prometheus to develop this phenomenon.    He talks about the limited credibility and utility of information shared on the subreddit WallStBets, and why people are waking up to the fact that investing success isn't nearly as easy as they may have initially thought. Mike later explains why the financial conditions we've enjoyed in recent times won't be returning for some time and why exposure to alternatives will be the key to investors protecting and growing their wealth in the months and years ahead.

Learn about the creative journey of a Chinese immigrant who served as a Green Beret and then started a medical device company that uses AI to make hospitals safer.  Michael Wang graduated from Emory University and Columbia University and is the founder of Inspiren, a clinician-led technology company that uses AI and computer vision to augment and improve clinical outcomes. He is a licensed advanced practice clinician specializing in Cardiothoracic Surgery and Acute Care. Prior to his entrepreneurial and medical career, he served as a Green Beret in the United States Army Special Forces.   Episode Links and Mentions: Mike's Link List:  Inspiren The restaurant Mike would take you to: Mógū: Modern Chinese Kitchen Keep an eye out for Mike's forthcoming book, Unbeaten! Follow Inspiren: Twitter | LinkedIn Episode Website/Newsletter: https://mailchi.mp/designlabpod/michaelwang More episode sources & links Sign-up for Design Lab Podcast's Newsletter Previous Episode Newsletters and Shownotes Follow @DesignLabPod on Twitter Instagram LinkedIn Facebook Follow @BonKu on Twitter & Instagram Check out the Health Design Lab Production by Robert Pugliese Edit by Fernando Queiroz Cover Design by Eden Lew Theme song by Emmanuel Houston Indexed in the Library of Congress: ISSN 2833-2032

In this episode of FWTH Andrew chats with Michael Wang, Veteran Fund Manager and CEO of Prometheus Alternative Investments. Andrew and Michael talk about democratizing access to hedge funds, retail investor education, and how to respond to volatility in the market.To learn more about Prometheus, visit: https://www.prometheusalts.com/Fintech, What the Heck? dives into the future of innovation in the finance field. Join Andrew Carpenter as he interviews industry experts, confers with coworkers, and discusses disruption in the field. Sponsored by Intrinio.  Intrinio is a financial data partner powering innovators at financial institutions, startups, and universities by delivering high-quality data through cutting-edge tools designed for developers and engineers, via an automated data supply chain. If you're creating the next big thing, we're here to help – see what it means to be #PoweredbyIntrinio at https://intrinio.com. 

Michael Wang is an award-winning hedge fund veteran. An alum of Steve Cohen's legendary SAC Capital, Wang contributed to Tourbillon Capital Partners' early success before winning accolades as Cypress Funds' portfolio manager and co-managing partner. He created Prometheus around his strong belief that everyone should have access to information and investment opportunities that, historically, have only been accessible to a select few. Laurel Mintz, founder and CEO of award-winning marketing agency Elevate My Brand, explores some of the most exciting new and growing brands in Los Angeles and the US at large. Each week, the Elevate Your Brand podcast features an entrepreneurial special guest to discuss the past, present and future of their brand.

This week on The MarketBeat Podcast Kate's guest is Michael Wang, founder of Prometheus Alternative Investments. Michael has done stints at Citigroup as well as hedge funds and understands the market from various perspectives. In this interview, he discusses why he believes institutional investors are positioned bearishly at this time, and how individuals should approach their portfolios as the summer rally seems to have fizzled. Topics in today's interview include: -Why Michael says “Do not conflate the market today with the economy today” -Why the summer rally was due to better-than-expected Q2 earnings, as well as lower commodity prices, despite high inflation numbers -Why tech stocks, along with other growth names, are sensitive to interest rates, affecting their share prices today -Was the summer uptrend just a bear market rally? It looks that way. -Will the market continue to hold above its mid-June lows? -In which sectors does Michael see potential right now? Does he see continued interest in so-called FANG names? -Why does Michael see strength in the semiconductor space, despite poor earnings or guidance? -How retailers like Target are pulling forward bad news, whereas pandemic darlings like Peloton pulled forward good news. -Investors know the economy is challenging, but they are managing their expectations about earnings reports for that reason -How 2009 and 2020 were good examples of why you shouldn't conflate the market with the economy. Markets price in economic recoveries before they happen. -Easy tips for holding stocks and avoid buying at the top and selling at the bottom Find Michael at www.prometheusalts.com Michael's special offer for MarketBeat listeners to access the Prometheus platform: https://app.prometheusalts.com/invite-code  Enter code: BIRD for access Links mentioned in this episode: https://www.marketbeat.com/all-access/ This podcast is hosted by ZenCast.fm

Michael Wang, the CEO of Prometheus Alternative Investments, joins the podcast today. Michael talks about how investors are adjusting amid the current market volatility, including what to expect as the Fed hikes rates.Become a smarter investor and make more money by subscribing to Early Bird, a free daily email newsletter, for free: http://earlybird.emailThe contents from Early Bird are for informational and entertainment purposes only and do not constitute financial or legal advice.

Michael Wang is a Co-founder and CEO of Telecare, one of the largest virtual healthcare clinics in Australia. Telecare provides accessible, affordable, and efficient healthcare across specialist and allied health fields. In today's episode, Michael details his journey in starting a virtual clinic, and how Telecare is combining business, technology, and medicine to provide a digital-first healthcare service experience that makes things easier for everyone involved. Michael also talks about the catalysts that inspired Telecare, and the ways that healthcare practice owners can improve their processes by removing tedious activities.  Key takeaways: Telecare is a digital-first healthcare clinic that is digitising the communication process between patients, specialists, and referrers, to remove the need for outdated technology such as faxes and smooth the private practice pipeline. COVID-19 has increased the demand for digital options, including Telehealth appointments, and Telecare is helping practitioners with this transition by providing a digital virtual clinic. Resources and links: Telecare website Connect with Michael Wang on LinkedIn Connect: Listen to other episodes of Reimagining Healthcare Connect with Yianni Serpanos on LinkedIn Follow HealthTechX on LinkedIn Follow HealthTechX on Instagram Follow HealthTechX on Meetup This show is produced in collaboration with Wavelength Creative. Visit wavelengthcreative.com for more information.

Prometheus Founder and CEO Michael Wang learns about Twitter accepting Elon Musk's $44B deal in real-time and shares his thoughts as the New York Stock Exchange halts trading TWTR. Mike explains why trading is halted in a situation like this, what Twitter will trade at when trading resumes, and whether this deal is good or bad news for shareholders. We talk about how Elon can create value by taking down Twitter's cost structure, the benefits of being a private company, and what the deal this means for free speech.

Jason Karp discovered that running an investment fund was no longer his calling at the very peak of his success. His mistake, he tells us, was not retiring from the industry at that exact moment. But by the time Jason shut Tourbillon Capital down in 2018, his calling was becoming clear—he wanted to help people live healthier lives. In the years before joining SAC Capital, managing the legendary firm's largest portfolio, Jason had been diagnosed with several autoimmune diseases. Rather than take medications to mitigate his symptoms, Jason rigorously investigated the effects of the food and products he consumed, gradually regaining his health. While achieving incredible success at Carlson Capital and later Tourbillon, Jason was growing Hu, a company he co-founded with his wife Jessica and brother-in-law Jordan. The award-winning chocolate they created is vegan, paleo, soy-free, refined sugar-free, and laid the groundwork for the HumanCo—the health-focused entity Jason founded in 2019.Jason shares his origin story as an entrepreneurial kid and under-aged card counter in our inspiring sit-down. He also tells us how his investment background and authentic personal health journey give him a massive edge in his mission to make healthier living more accessible for more people.

Nurses create iN: The World's First Cognitive Patient Care Assistant and become founders of an award winning technology company. View the full video interview here. Michael Wang and Paul Coyne are nurses, friends, the founders of Inspiren and the inventors of iN, the world's first cognitive patient care assistant. iN is a hybrid sensing, wall-mounted device, that uses computer vision, deep learning, BLE, and multiple sensors, to identify and analyze the hospital environment, including the interactions of people and medical equipment within a hospital room.

For our final show of 2021, we welcome WSOP bracelet winner Leo Margets. We also sit down with another bracelet winner, top pro Michael Wang. For strategy, Bertie ‘Bigstealer' Bayley is here to discuss a fascinating hand from the 500 Zoom cash game streets. Paul Seaton stops to ask Dara and David about being poker ambassadors. Plus, Ian's got news and results.

Guest: Michael Wang, MD What can we look forward to seeing at the 63rd American Society of Hematology Annual Meeting and Exposition? Dr. Michael Wang shares anticipated updates in mantle cell lymphoma, or MCL.

If the COVID-19 pandemic taught us one thing about healthcare it was that American consumers are open to new ways of receiving care. But is this also true for older adults -- who are accustomed to the traditional medical office setting? The answer is 'yes', according to Drs. Scott Weingarten and Michael Wang, leaders of a new medical group for older adults. The new group will emphasize telemedicine, home visits and other creative approaches for tailoring care to older patients.

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US, and Peter Martin, Weill Cornell Medicine, New York, US. We asked, What does real-world data tell us about frontline treatment strategies for mantle cell lymphoma (MCL)? To answer this question, Martin firstly evaluates data from a retrospective study, which included adult patients with MCL in the nationwide Flatiron Health EHR-derived deidentified database. He describes the results in 3,455 previously untreated patients, including treatment patterns in real-world clinical practice and how they compare with clinical studies, patient outcomes, and the role of stem cell transplantation. Wang then shares his opinion on these data, focusing on the time gap between frontline clinical data and changes to practice patterns. He also outlines further data on promising novel regimens for patients with MCL. Hosted on Acast. See acast.com/privacy for more information.

Bodies exceed humanity. They remind us that we are part of something vaster—and smaller—more complex, more connected than our mere existence as an atomized species. Our bodies, and bodies in general, are comprised of heterogeneity and multitudes. All bodies are wet collective bodies defined by how they link to other bodies, places, environments, technologies. Think of breathing, clogging, decomposing, discharging, flushing, lubricating, melting, menstruating, transfusing. Bodies exist as trans- and extra-territorial beings. They live in hybridity. This porous condition produces a planetary wet-togetherness, a “commoning” force that constitutes all bodies as collective hydro-subjects. Wet-Togetherness is a collaboration between e-flux and the 13th Shanghai Biennale, Bodies of Water, curated by Andrés Jaque, Marina Otero Verzier, Lucia Pietroiusti, Filipa Ramos, and YOU Mi, and organized and promoted by the Power Station of Art. It consists of nine sound pieces in which 21 artists, activists, and researchers enact aqueousness through sound. The series has been edited by José Luis Espejo and Rubén Coll, with sound design by Tomoko Sauvage, coordination by Roberto González García, and locutions by Yang Yang.   Episode 5. Melting: With two sound pieces by the artists Cao Minghao and Chen Jianjun (in collaboration) and Michael Wang It is precisely at the melting point of a pure substance that solid and liquid forms coexist and produce each other. Glaciers and seas. Mountains and rivers. Molten rocks, soils, and climates. Entire worlds—several hundred to several thousand years old—melt into other worlds, making unexpected currents, struggles, and living conditions emerge. Cao Minghao and Chen Jianjun reflect on the impact that local policies and post-disaster reconstruction plans had in the Minjiang River after the 2008 Sichuan earthquake, and the way they were mitigated and responded to by local traditions, ancient wisdom, and more-than-human intelligences. Michael Wang's sound piece is attuned to the complex territorial entanglements that connect Shanghai to the melting glaciers of the Tibetan plateau and to the course of the Yangtze River. Ultimately, this work interrogates the power and intrinsic violence of reversibility.

February 2021 Journal Club Podcast Enhanced Recovery after Surgery (ERAS) Pathway for Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion Decreases Length of Stay and Opioid Consumption CNS Podcast Co-chair and Moderator: Tiffany Hodges, MD Author: Mena Kerolus, MD Faculty/Discussants: Matthew Cummock, MD and Michael Wang, MD Resident Fellow: Nitesh Patel, MD

Michael Wang is a graduate of Cornell Tech, CTO of Bowtie, and Futurist. This episode is all about starting an AI startup, what makes good software engineering teams, and what AI will look like in the next 50 years. Enjoy the show. Support this podcast: cutt.ly/Eh6zJog --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Dr Michael Wang a supply chain expert from AUT on how vulnerable our ports are. 

"I would never have learned that this SP was as nervous as me had I not taken his pulse. ... As imaging technology and electronic records pull us away from the bedside, perhaps the unique privilege of performing something as intimate as the physical exam will help us keep the patient at the center of our care." Medical student Michael Wang reflects on a standardized patient encounter that reminded him about the genuine connection between patients and physicians that can come from the physical exam.   This essay was published in the Teaching and Learning Moments column in the August 2020 issue of Academic Medicine. Read the essay at academicmedicine.org.

Jazz am Sunntig uf Radio RaBe - die Jazzsändig für Bärn! Mit Athina Dill, Manon Mullener, Christian Schütz und Simon Petermann Michael Wang.mp3

Michael Wang, founder and CEO of Inspiren (https://inspiren.com), and Rohit Prakash, founder and CEO of Coast App (https://coastapp.com), talk about how their companies are making a difference helping healthcare and frontline workers during the COVID crisis.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Michael Yang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson, discuss recent clinical advances in mantle cell lymphoma

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Michael Yang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson, discuss recent clinical advances in mantle cell lymphoma

This week Alan talks with Michael Wang about his debut album release, his background, what he learned from leading his first recording session, and life in New York City.

Matt Cutts is the Administrator of the US Digital Service and previously he was the head of the webspam team at Google.You can find him on Twitter at @mattcutts.The YC podcast is hosted by Craig Cannon.Y Combinator invests a small amount of money ($150k) in a large number of startups (recently 200), twice a year.Learn more about YC and apply for funding here: https://www.ycombinator.com/apply/ ***Topics00:00 - Intro00:36 - Working at Google in 20002:48 - Did Google's success feel certain?3:53 - Building self-service ads7:23 - The evil unicorn problem8:23 - Lawsuits around search10:48 - Content moderation and spam14:38 - Matt's progression over 17 years at Google17:18 - Deepfakes18:43 - Joining the USDS21:03 - What the USDS does23:43 - Working at the USDS26:43 - Educating people in government about tech28:58 - Creating a rapid feedback loop within government31:48 - Michael Wang asks - How does USDS decide whether to outsource something to a private company, or build the software in house?32:58 - Spencer Clark asks - It would seem that the government is so far behind the private industry’s technology. To what extent is this true and what can be done about it? How should we gauge the progress of institutions like the USDS?36:03 - Stephan Sturges asks - With GANs getting more and more powerful is the USDS thinking about the future of data authenticity?38:23 - John Doherty asks - How difficult was it to communicate Google’s algorithm changes and evolving SEO best practices without leaking new spam tactics?40:18 - Vanman0254 asks - How can smart tech folks better contribute to regulatory and policy discussions in government? 42:38 - Ronak Shah asks - What's your best pitch to high-performing startups in the Bay Area to adopt more of human centered design (something that the government has been moving towards surprisingly well, but that some fast moving startups have neglected resulting in controversy)49:58 - Adam Hoffman asks - What are legislators, the government, and the general populace most “getting wrong” in how they conceptualize the internet?51:33 - Raphael Ferreira asks - Is it possible to live without google? How do you think google affected people in searching for answers and content, now that’s we find everything in just one click?55:23 - Tim Woods asks - Which job was more fun and why?57:13 - Working in government vs private industry1:00:48 - Snehan Kekre asks - What is Matt's view of the ongoing debate about backdooring encryption for so called lawful interception?

As we enter into a new phase of hemophilia treatments and products, the questions continue to grow and become more complicated by the day. Check out the latest episode of Ask the Expert, where we welcome Dr. Michael Wang, M.D. from the University of Colorado Hemophilia and Thrombosis center to discuss the current status of revolutionary potential treatments like gene therapy and non-factor replacements. Dr. Wang answers listeners own questions about the clinical trial process, research updates, what the medical community is encouraged about, as well as concerns being raised. In this true paradigm shift in how we view hemophilia treatment, the only consistent message from all sides as been - educate yourself and keep asking questions. Join us for a can’t miss episode of Ask the Expert!   Welcome to Episode 33 - or our Paradigm Shift in Hemophilia Treatment Episode - of the Ask The Expert Podcast!  ‍ For the latest in clinical trial outcomes follow the National Hemophilia Foundation https://www.hemophilia.org/ ‍ “Strong gene therapy candidates are encouraged to have meticulous logging skills and the availability to be seen every week for a period of time.” Dr. Michael Wang, M.D.   “The future will be about individualized choice based on lifestyle and the type of protection you want in a treatment.” Dr. Michael Wang, M.D.   “We will begin to understand mild/moderate patients in depth going forward because of the treatment shift due to sheer volume.” Dr. Michael Wang, M.D. 

The United Nations Sustainable Development Goal No. 1: End poverty in all its forms everywhere Source: https://www.un.org/sustainabledevelopment/poverty/ In this episode, Maria Bach explores how poverty has been defined and measured over time inspired by her work with Mary Morgan recently published in the History of Political Economy Journal (https://read.dukeupress.edu/hope/issue/50/S1) The episode features notably Amartya Sen, Frances Stewart, Stephen Marglin and Mary Morgan. Here is a list of the books, websites and articles mentioned in the episode:1. GSDRC's definition of poverty2. UNESCO's definition of poverty3. The Economist's article on defining poverty4. Poverty and Social Exclusion Project based in the UK5. Jean Dreze and Amartya Sen's An Uncertain Glory, 20136. Howard Glennerster, John Hills, David Pichaud and Jo Webb's One Hundred Years of Poverty and Policy, 20047. Seebohm Rowntree's Poverty: A Study of Town Life, 19088. The New York Times article on How to define poverty? by Louis Uchitelle, 20019. The UN Intellectual History Project10. The IMF and World Bank's Poverty Reduction Strategy Papers (PRSPs)11. Frances Stewart and Michael Wang's working paper on Do PRSPs empower poor countries and disempower the World Bank, or is it the other way round?

Michael Wang is Founder & CEO of Inspiren, an award winning healthcare technology company. He is a registered nurse and nurse practitioner with vast clinical experience in cardiothoracic surgery and direct patient care. In addition, he holds numerous patents on innovate technologies in both the healthcare and hospitality industry and has founded two successful companies prior to Inspiren. He received a bachelors degree from Emory University, majoring in Biology and Sociology. He attended graduate school at Columbia University, studying both business and nursing. Website: http://inspiren.com/   https://www.sonsiel.com/

Today's Guest: Paul Coyne, DNP | President & Co-Founder of Inspiren Greg and Paul talk about the unique life experiences that drove he and Inspiren co-founder Michael Wang to create Inspiren - the first cognitive patient assistant. Important Links: Inspiren web site: http://inspiren.com/ Inspiren on Twitter: https://twitter.com/InspirenHealth Paul on LinkedIn: https://www.linkedin.com/in/paulecoyne/ SONSIEL Nurse Innovator Organization: https://www.sonsiel.com/  For more, visit the DataPoint show page at http://touchpoint.health/shows/datapoint/.

At age 26, Paul Coyne had to leave Goldman Sachs because of the residual of the stroke that happened to him. Undeterred, Paul returned to school to prove that despite a challenging stroke recovery and a congenital heart disease, he is still capable of great success. In the next 4-years, Paul obtained 5 degrees including a Doctorate from Columbia University School of Nursing as well as an MBA in Healthcare Management and a MS, Finance from Northeastern University. In addition, with his friend Michael Wang, Paul launched Inspiren, which is rapidly gaining traction in the medical world, leveraging Artificial Intelligence to revolutionize the nursing process. Today, Dr. Coyne is a board-certified nurse practitioner in Adult-Gerontology with sub-specialty in palliative care and his writings on end-of-life care have been published in academic journals. Columbia named him one of 9 great graduates of their entire university of 2016 upon completion of his doctorate. Listen to his remarkable story and get to know Dr Coyne.

Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?

Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?

Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?

Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care?

Episode 11: “Go Live LIVE.” “Go Live” is the official podcast from the AMIA Clinical Informatics Fellows (ACIF). This episode recorded live from AMIA 2017: CDS interoperability, ACIF at AMIA, Women in Informatics, (and more) Host: Chase Parsons Co-hosts: Mark Zhang, Jamie Bell, Chancey Christiensen, Michael Wang, Melissa Van Cain Recorded Live from AMIA 2017: CDS interoperability, ACIF at AMIA, Women in Informatics, (and more) ProTips: Ask (Chase), Mentoring at AMIA / Cargoship Travel (Zhang), Google Trips / a SwitchHouse (Bell), Rolling your stuff (Chancey / Japan), Splashtop (Wang), Forget and Ask (Van Cain)

Today we catch up with my good friend Michael Wang, who is currently COO of YCloset, an online clothing rental and subscription service that raised $20m Series B in March and has already scaled to 40 cities in China. Before YCloset, Michael was on the other side of the table, having spent a few years at KKR before joining IDG Capital, where he was also the lead investor for YCloset's Series A+ round. As such, Michael offers a unique view, speaking from both an operator and investor perspective, and can help us understand the following: Clothing rental companies only recently became popular in China, whereas comparable companies abroad such as Rent The Runway have been around since 2009… what's different now? How does YCloset compare against global and domestic competitors? What are key success factors in this market, from optimizing logistics to central dry cleaning to capital accessibility? What role do China's tech giants (e.g. Alibaba or JD) play in this arena? What is the "rent-to-buy" model, and what might this market look like in the near to medium term? Link to write-up here: https://www.theharbingerchina.com/blog/rent-to-buy-the-chinese-runway-with-ycloset-coo-michael-wang

Gary has Dr. Michael Wang from the University of Michigan, who is leading the research in CADASIL, call in to discuss his younger brother's Scott's condition with this genetic illness. CADASIL causes the brain to manufacture white matter, which results in damage to the brain.This show is broadcast live Tuesday's at 12:00AM ET on W4CY Radio – (www.w4cy.com) part of Talk 4 Radio (http://www.talk4radio.com/) on the Talk 4 Media Network (http://www.talk4media.com/).

Today we catch up with my good friend Michael Wang, who is currently COO of YCloset, an online clothing rental and subscription service that raised $20m Series B in March and has already scaled to 40 cities in China. Before YCloset, Michael was on the other side of the table, having spent a few years at KKR before joining IDG Capital, where he was also the lead investor for YCloset's Series A+ round. As such, Michael offers a unique view, speaking from both an operator and investor perspective, and can help us understand the following: Clothing rental companies only recently became popular in China, whereas comparable companies abroad such as Rent The Runway have been around since 2009… what's different now? How does YCloset compare against global and domestic competitors? What are key success factors in this market, from optimizing logistics to central dry cleaning to capital accessibility? What role do China's tech giants (e.g. Alibaba or JD) play in this arena? What is the "rent-to-buy" model, and what might this market look like in the near to medium term?

Gary discusses his trip ti Michigan with his younger brother Scott and their visit with Dr. Michael Wang at the University of Michigan. Scott has Cadasil, which is a rare genetic mutation that affects his brain function.This show is broadcast live Tuesday's at 12:00AM ET on W4CY Radio – (www.w4cy.com) part of Talk 4 Radio (http://www.talk4radio.com/) on the Talk 4 Media Network (http://www.talk4media.com/).

MD Anderson's cancer Moon Shots Program is a comprehensive and ambitious effort to reduce the incidence and mortality of cancer. Several new cancers recently were added to the program, including B-cell lymphoma. In this podcast, the co-leaders of the B-cell Lymphoma Moon Shot, Michael Wang, M.D., professor of Lymphoma/Myeloma, and Richard Champlin, M.D., chair of Stem Cell Transplantation, explain why this disease was chosen for the Moon Shots Program.

Ongoing clinical research at MD Anderson is finding promising new therapies for a rare and aggressive type of lymphoma that becomes resistant to treatment. Although mantle cell lymphoma (MCL) currently has no cure, combinations of new targeted therapy drugs are dramatically improving survival and treatment response rates for MCL patients. MD Anderson lymphoma specialists Jorge Romaguera, M.D. and Michael Wang, M.D., discuss these mantle cell lymphoma treatments and their search for new pathways that may lead to a cure.

Mantle cell lymphoma (MCL) is a rare form of blood cancer belonging to the disease group classified as non-Hodgkin's lymphoma. Only 3-6% of all non-Hodgkin’s lymphoma cases in the United States are MCL. Michael Wang, M.D., associate professor, and Jorge Romaguera, M.D., professor, both in Lymphoma/Myeloma at MD Anderson Cancer Center, discuss this disease that forms in the lymph node region known as the mantle zone.